ProPhase Labs, Inc. Increase (Decrease) in Deferred Income Taxes
ProPhase Labs, Inc. (PRPH) reported Increase (Decrease) in Deferred Income Taxes of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredIncomeTaxes · last filed 2026-06-01
- ProPhase Labs, Inc. increase (decrease) in deferred income taxes for the quarter ending 2025-12-31 was $0.00.
- ProPhase Labs, Inc. increase (decrease) in deferred income taxes for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. increase (decrease) in deferred income taxes for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. increase (decrease) in deferred income taxes for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. increase (decrease) in deferred income taxes for fiscal 2025 was $0.00.
- ProPhase Labs, Inc. increase (decrease) in deferred income taxes for fiscal 2024 was -$7.15M, a 197.77% decline from fiscal 2023.
- ProPhase Labs, Inc. increase (decrease) in deferred income taxes for fiscal 2023 was $7.31M, a 5199.28% increase from fiscal 2022.
- ProPhase Labs, Inc. increase (decrease) in deferred income taxes for fiscal 2022 was $138.00K.
| Period end | Increase (Decrease) in Deferred Income Taxes 3 month | Increase (Decrease) in Deferred Income Taxes 3 month as first filed | Increase (Decrease) in Deferred Income Taxes 6 month | Increase (Decrease) in Deferred Income Taxes 6 month as first filed | Increase (Decrease) in Deferred Income Taxes 9 month | Increase (Decrease) in Deferred Income Taxes 9 month as first filed | Increase (Decrease) in Deferred Income Taxes 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $0.00 derived: sum of 2 quarters · filed 2026-06-01 | $0.00 derived: sum of 3 quarters · filed 2026-06-01 | $0.00 10-K · filed 2026-06-01 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2025-11-19 | $0.00 10-Q · filed 2025-11-19 | -$14.58M derived: sum of 4 quarters · filed 2026-06-01 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | -$14.58M derived: sum of 3 quarters · filed 2026-06-01 | -$12.05M derived: sum of 4 quarters · filed 2026-06-01 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-20 | -$14.58M derived: sum of 2 quarters · filed 2026-06-01 | -$12.05M derived: sum of 3 quarters · filed 2026-06-01 | -$9.76M derived: sum of 4 quarters · filed 2026-06-01 | |||
| 2024-12-31 | -$14.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$12.05M derived: sum of 2 quarters · filed 2026-06-01 | -$9.76M derived: sum of 3 quarters · filed 2026-06-01 | -$7.15M 10-K · filed 2026-06-01 | |||
| 2024-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $4.82M derived: sum of 2 quarters · filed 2025-11-19 | $7.43M 10-Q · filed 2025-11-19 | $0.00 10-Q · filed 2024-11-13 | $14.43M derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $4.90M 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2024-08-14 | $11.91M derived: sum of 3 quarters · filed 2025-08-13 | $11.91M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $2.61M 10-Q · filed 2025-05-20 | $9.62M derived: sum of 2 quarters · filed 2025-05-20 | $9.62M derived: sum of 3 quarters · filed 2025-05-20 | $9.83M derived: sum of 4 quarters · filed 2025-05-20 | |||
| 2023-12-31 | $7.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $7.01M derived: sum of 2 quarters · filed 2025-04-01 | $7.22M derived: sum of 3 quarters · filed 2025-04-01 | $7.31M 10-K · filed 2025-04-01 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $211.00K derived: sum of 2 quarters · filed 2024-11-13 | $307.00K 10-Q · filed 2024-11-13 | $4.35M 10-Q · filed 2023-11-13 | -$894.00K derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $211.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $307.00K 10-Q · filed 2024-08-14 | $1.79M 10-Q · filed 2023-08-11 | -$894.00K derived: sum of 3 quarters · filed 2024-08-14 | -$149.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $96.00K 10-Q · filed 2023-05-12 | -$1.10M derived: sum of 2 quarters · filed 2023-05-12 | -$360.00K derived: sum of 3 quarters · filed 2023-11-13 | $234.00K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$456.00K derived: sum of 2 quarters · filed 2023-11-13 | $138.00K derived: sum of 3 quarters · filed 2023-11-13 | $138.00K 10-K · filed 2023-03-29 | |||
| 2022-09-30 | $745.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.34M derived: sum of 2 quarters · filed 2023-11-13 | $1.34M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $594.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $594.00K 10-Q · filed 2023-08-11 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-12 | -$443.00K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |